Prema P Peethambaram

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Her-2/neu expression in ovarian cancer: pre- and postexposure to platinum chemotherapy
    Prema P Peethambaram
    Mayo Clinic, Rochester, MN 55905, USA
    Gynecol Oncol 89:99-104. 2003
  2. pmc A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu
    Prema P Peethambaram
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 15:5937-44. 2009
  3. pmc Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer
    Evanthia Galanis
    Division of Medical Oncology, Department of Molecular Medicine, Mayo Clinic, Gonda 10 141, 200 First Street Southwest, Rochester, MN 55905, USA
    Cancer Res 70:875-82. 2010
  4. ncbi request reprint A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261
    Keith C Bible
    Division of Medical Oncology, Department of Health Science Research, Mayo Clinic, Rochester, MN 55905, USA
    Gynecol Oncol 127:55-62. 2012
  5. pmc A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma
    Andrea E Wahner Hendrickson
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Gynecol Oncol 124:210-5. 2012
  6. pmc Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma
    S John Weroha
    Department of Medical Oncology, Mayo, Rochester, MN 55905, USA
    Gynecol Oncol 122:116-20. 2011
  7. pmc Inherited determinants of ovarian cancer survival
    Ellen L Goode
    Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Clin Cancer Res 16:995-1007. 2010
  8. pmc Consumer beware: a systematic assessment of potential bias in the lay electronic media to examine the portrayal of "PARP" inhibitors for cancer treatment
    Shawnta Coleman
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Cancer Educ 26:474-7. 2011
  9. doi request reprint Are cancer survivors/patients knowledgeable about osteoporosis? Results from a survey of 285 chemotherapy-treated cancer patients and their companions
    Heidi McKean
    Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Nutr Educ Behav 40:144-8. 2008
  10. pmc Assessment of hepatocyte growth factor in ovarian cancer mortality
    Ellen L Goode
    Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 20:1638-48. 2011

Collaborators

Detail Information

Publications14

  1. ncbi request reprint Her-2/neu expression in ovarian cancer: pre- and postexposure to platinum chemotherapy
    Prema P Peethambaram
    Mayo Clinic, Rochester, MN 55905, USA
    Gynecol Oncol 89:99-104. 2003
    ..Our objective was to determine if the level of Her-2/neu expression in advanced ovarian cancer changed after platinum-based chemotherapy...
  2. pmc A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu
    Prema P Peethambaram
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 15:5937-44. 2009
    ....
  3. pmc Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer
    Evanthia Galanis
    Division of Medical Oncology, Department of Molecular Medicine, Mayo Clinic, Gonda 10 141, 200 First Street Southwest, Rochester, MN 55905, USA
    Cancer Res 70:875-82. 2010
    ..Our findings indicate that i.p. administration of MV-CEA is well tolerated and results in dose-dependent biological activity in a cohort of heavily pretreated recurrent ovarian cancer patients...
  4. ncbi request reprint A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261
    Keith C Bible
    Division of Medical Oncology, Department of Health Science Research, Mayo Clinic, Rochester, MN 55905, USA
    Gynecol Oncol 127:55-62. 2012
    ..Based upon promising preclinical and phase 1 trial results, combined flavopiridol and cisplatin therapy was evaluated in patients with ovarian and primary peritoneal cancers...
  5. pmc A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma
    Andrea E Wahner Hendrickson
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Gynecol Oncol 124:210-5. 2012
    ..To assess the effect of tanespimycin on tumor cells, levels of the chaperone proteins HSP90 and HSP70 were examined in peripheral blood mononuclear cells (PBMC) and paired tumor biopsy lysates...
  6. pmc Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma
    S John Weroha
    Department of Medical Oncology, Mayo, Rochester, MN 55905, USA
    Gynecol Oncol 122:116-20. 2011
    ..We designed a phase II clinical trial evaluating the efficacy and adverse event profile of concomitant topotecan and lapatinib, a small molecule pan-erbB inhibitor that can block BCRP/Pgp efflux of topotecan...
  7. pmc Inherited determinants of ovarian cancer survival
    Ellen L Goode
    Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Clin Cancer Res 16:995-1007. 2010
    ....
  8. pmc Consumer beware: a systematic assessment of potential bias in the lay electronic media to examine the portrayal of "PARP" inhibitors for cancer treatment
    Shawnta Coleman
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Cancer Educ 26:474-7. 2011
    ..it's the kind of thing you don't really think will happen". Healthcare providers should be aware of the foregoing when discussing PARP inhibitors-and perhaps other novel therapies-with cancer patients...
  9. doi request reprint Are cancer survivors/patients knowledgeable about osteoporosis? Results from a survey of 285 chemotherapy-treated cancer patients and their companions
    Heidi McKean
    Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Nutr Educ Behav 40:144-8. 2008
    ..This study assessed osteoporosis knowledge deficits among cancer patients and their spouses/partners...
  10. pmc Assessment of hepatocyte growth factor in ovarian cancer mortality
    Ellen L Goode
    Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 20:1638-48. 2011
    ..Invasive ovarian cancer is a significant cause of gynecologic cancer mortality...
  11. ncbi request reprint Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma
    Evanthia Galanis
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 101:2557-66. 2004
    ..In the current study, the authors investigated the safety and efficacy of in situ vaccination with Leuvectin in patients with metastatic renal cell carcinoma...
  12. ncbi request reprint Pelvic primitive neuroectodermal tumor associated with a cluster of small round cell tumors: case report and review of current literature
    Bobbie S Gostout
    Section of Gynecologic Surgery, Mayo Clinic, Rochester, MN 55905, USA
    Gynecol Oncol 91:247-53. 2003
    ..Peripheral primitive neuroectodermal tumor (pPNET) is aggressive and rare, comprising 1% of soft tissue sarcomas. Involvement of the reproductive tract is unusual...
  13. ncbi request reprint A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer
    Grace K Dy
    Department of Oncology, Division of Medical Oncology, Mayo Clinic and Foundation, 200 First St SW, Rochester, MN 55905, USA
    Cancer Chemother Pharmacol 56:623-8. 2005
    ....
  14. ncbi request reprint Second-line and subsequent therapy for ovarian carcinoma
    Prema P Peethambaram
    Division of Medical Oncology, Department of Oncology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    Curr Oncol Rep 4:159-64. 2002
    ..Whole abdominal radiotherapy for relapsed microscopic disease should be studied in prospective randomized trials. Women with advanced ovarian carcinoma should continue to be encouraged to participate in well-designed clinical trials...